NEJM:多替拉韦或达芦那韦联合齐多夫定或替诺福韦治疗HIV感染的比较的析因研究(NADIA研究)

2021-07-25 MedSci原创 MedSci原创

世界卫生组织推荐将多替拉韦联合两种核苷逆转录酶抑制剂(NRTI)用于人类免疫缺陷病毒1型(HIV-1)感染的二线治疗。该治疗方案对于以下情况的疗效证据有限:因耐药而预计NRTI缺乏抗病毒活性时,以及推

世界卫生组织推荐将多替拉韦联合两种核苷逆转录酶抑制剂(NRTI)用于人类免疫缺陷病毒1型(HIV-1)感染的二线治疗。该治疗方案对于以下情况的疗效证据有限:因耐药而预计NRTI缺乏抗病毒活性时,以及推荐的将NRTI从替诺福韦换成齐多夫定。

方法

在一项2×2析因、开放标签、非劣效性试验中,我们将一线治疗失败(HIV-1病毒载量,≥1000 copies/mL)的患者随机分组,分别接受多替拉韦或利托那韦增强达芦那韦治疗,并且接受替诺福韦或齐多夫定治疗;所有患者均接受了拉米夫定治疗。主要结局是按照美国食品药品管理局快照算法,第48周的病毒载量<400 copies/mL(对于发生主要结局的患者百分比的组间差异,非劣效性界值为12个百分点)。

结果

我们在撒哈拉以南非洲地区的7个研究中心纳入了464例患者。在多替拉韦组90.2%的患者(212/235)和达芦那韦组91.7%的患者(210/229)(差异,-1.5%;95%置信区间[CI],-6.7~3.7;P=0.58;证明了多替拉韦的非劣效性,但未证明优效性)中,以及在替诺福韦组92.3%的患者(215/233)和齐多夫定组89.6%的患者(207/231)(差异,2.7%;95% CI,-2.6~7.9;P=0.32;证明了替诺福韦的非劣效性,但未证明优效性)中,我们观察到第48周的病毒载量<400 copies/mL。在预计NRTI缺乏抗病毒活性的患者亚组中,我们在多替拉韦组和达芦那韦组90%以上的患者中观察到病毒载量<400 copies/mL。在任何一项析因比较分析中,不良事件发生率均无显著组间差异。

结论

多替拉韦联合NRTI可有效治疗HIV-1感染患者,包括预计NRTI缺乏抗病毒活性的广泛NRTI耐药患者。作为二线治疗,替诺福韦不劣于齐多夫定。(由杨森公司资助;NADIA在ClinicalTrials.gov注册号为NCT03988452。)

Background
The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine.
Methods

In a two-by-two factorial, open-label, noninferiority trial, we randomly assigned patients for whom first-line therapy was failing (HIV-1 viral load, ≥1000 copies per milliliter) to receive dolutegravir or ritonavir-boosted darunavir and to receive tenofovir or zidovudine; all patients received lamivudine. The primary outcome was a week 48 viral load of less than 400 copies per milliliter, assessed with the Food and Drug Administration snapshot algorithm (noninferiority margin for the between-group difference in the percentage of patients with the primary outcome, 12 percentage points).

Result

We enrolled 464 patients at seven sub-Saharan African sites. A week 48 viral load of less than 400 copies per milliliter was observed in 90.2% of the patients in the dolutegravir group (212 of 235) and in 91.7% of those in the darunavir group (210 of 229) (difference, −1.5 percentage points; 95% confidence interval [CI], −6.7 to 3.7; P=0.58; indicating noninferiority of dolutegravir, without superiority) and in 92.3% of the patients in the tenofovir group (215 of 233) and in 89.6% of those in the zidovudine group (207 of 231) (difference, 2.7 percentage points; 95% CI, −2.6 to 7.9; P=0.32; indicating noninferiority of tenofovir, without superiority). In the subgroup of patients with no NRTIs that were predicted to have activity, a viral load of less than 400 copies per milliliter was observed in more than 90% of the patients in the dolutegravir group and the darunavir group. The incidence of adverse events did not differ substantially between the groups in either factorial comparison.

Conclusions

Dolutegravir in combination with NRTIs was effective in treating patients with HIV-1 infection, including those with extensive NRTI resistance in whom no NRTIs were predicted to have activity. Tenofovir was noninferior to zidovudine as second-line therapy. (Funded by Janssen; NADIA ClinicalTrials.gov number, NCT03988452.)
原始出处:
Nicholas I. Paton, Joseph Musaazi, Cissy Kityo, et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. DOI: 10.1056/NEJMoa2101609

版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (1)
#插入话题
  1. 2021-07-25 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

MedRxiv:新冠病毒在艾滋病患者体内快速突变,导致新冠病毒加速进化、更加强大

新冠病毒导致的新冠肺炎疫情如今已经导致了全世界超过 1.8 亿人感染,造成超过 400 万人死亡,目前,全世界许多国家和地区的新冠感染人数仍在快速增长。接种疫苗是抵抗新冠病毒最有力的措施,然而,随着新

STTT:脐带间充质干细胞成功帮助艾滋病患者免疫重建

近日,中国人民解放军总医院第五医学中心王福生院士团队在 Signal Transduction and Targeted Therapy 上在线发表了一篇研究论文。该研究发现, 脐带间充质干

Nature Medicine:深度学习快速检测艾滋病

该研究经证明了深度学习对RDT图像的准确分类的潜力,其整体性能的准确率为98.9%,明显高于研究参与者的传统视觉解释(92.1%),而报告的准确率为80-97%。

NEJM:艾滋病人群心源性猝死机率更高

加州大学旧金山分校发表在新英格兰医学杂志 (NEJM) 上的研究显示,与普通人群相比,感染 HIV 的个体死于心源性猝死 (SCD) 的可能性是普通人群的两倍以上。

Nature Commun:硬核预防HIV,艾滋病还会是“不治之症”吗?

1981年6月5日,美国疾病预防控制中心登载了5例艾滋病病人的病例报告,这是艾滋病在世界上的首次正式记载。人类致力于攻克艾滋病已有40年历史,期间曾有两例艾滋病治愈案例为大家所熟知,这一切似乎都预示着

打开APP